Canna~Fangled Abstracts

Cannabis use and reduced risk of elevated fatty liver index in HIV-HCV co-infected patients: a longitudinal analysis (ANRS CO13 HEPAVIH)

By February 4, 2021February 5th, 2021No Comments
Cannabis use is associated with a reduced risk of elevated fatty liver index in HIV-HCV co-infected patients.
. 2021 Feb 4.

doi: 10.1080/14787210.2021.1884545.

Online ahead of print.
Tangui Barre 1 2, Teresa Rojas Rojas 1 2 3, Karine Lacombe 4 5, Camelia Protopopescu 1 2, Isabelle Poizot-Martin 1 3, Marie Nishimwe 1 2, David Zucman 6, Laure Esterle 7, Eric Billaud 8 9, Hugues Aumaitre 10, Olivier Bouchaud 11 12, David Rey 13, Lionel Piroth 14 15, Dominique Salmon-Ceron 16 17, Linda Wittkop 7 18, Philippe Sogni 17 19 20, Maria Patrizia Carrieri 1 2, Lawrence Serfaty 21 22, Fabienne Marcellin 1 2
Affiliations 

Abstract

Background: Cannabis use and elevated fatty liver index (FLI≥ 60) (a biomarker of hepatic steatosis in the general population) have been identified as predictors of HCV-related and overall mortality, respectively, in HIV-HCV co-infected patients. However, the relationship between cannabis use and the risk of elevated FLI has never been explored.

Methods: Using five-year follow-up data from 997 HIV-HCV co-infected patients (ANRS CO13 HEPAVIH cohort), we analyzed the relationship between cannabis use and FLI using mixed-effects multivariable logistic (outcome: elevated FLI yes/no) and linear (outcome: continuous FLI) regression models.

Results: At the last follow-up visit, 27.4% of patients reported regular or daily cannabis use and 27.8% had elevated FLI. After multivariable adjustment, regular or daily cannabis use was associated with a 55% lower risk of elevated FLI (adjusted odds ratio [95% confidence interval]: 0.45 [0.22; 0.94]; p = 0.033) and lower FLI values (adjusted model coefficient: -4.24 [-6.57; -1.91], p<0.0001).

Conclusions: Cannabis use is associated with a reduced risk of elevated fatty liver index in HIV-HCV co-infected patients. Further research is needed to confirm whether and how cannabinoids may inhibit the development of hepatic steatosis or other metabolic disorders in high-risk populations.

Keywords: Cannabis, Fatty liver, Hepatitis C, Human immunodeficiency virus, Metabolic diseases, chronic

References

REFERENCES

    1. Grigsby TM, Hoffmann LM, Moss MJ. Marijuana use and potential implications of marijuana legalization. Pediatr Rev. 2020;41(2):61-72.
    1. National Institute on Drug Abuse. What is the scope of marijuana use in the United States? https://www.drugabuse.gov/publications/research-reports/marijuana/what-s…. Published 2020. Accessed May 30, 2020.
    1. Hasin DS, Saha TD, Kerridge BT, et al. Prevalence of marijuana use disorders in the United States between 2001-2002 and 2012-2013. JAMA Psychiat. 2015;72(12):1235-1242.
    1. National Institute on Drug Abuse. Is marijuana addictive? https://www.drugabuse.gov/publications/research-reports/marijuana/mariju…. Published 2020. Accessed May 30, 2020.
    1. Fattore L, Fadda P, Spano MS, Pistis M, Fratta W. Neurobiological mechanisms of cannabinoid addiction. Mol Cell Endocrinol. 2008;286(1-2 Suppl 1):S97-S107.

Grant support

Leave a Reply